These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24860905)

  • 21. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New drugs: watch out for unexpected adverse effects.
    Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of pharmacovigilance on drug portfolio management.
    Bucurescu S
    Eur Rev Med Pharmacol Sci; 2014; 18(15):2237-9. PubMed ID: 25070831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Problems encountered in the pharmacovigilance of violence and aggression.
    Prescrire Int; 2014 Jun; 23(150):154. PubMed ID: 25121149
    [No Abstract]   [Full Text] [Related]  

  • 27. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Quantification of pharmacological progress by the French National Health Authorities].
    Bouvenot G
    Bull Acad Natl Med; 2006; 190(4-5):893-903; discussion 903-4. PubMed ID: 17195614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced corneal damage.
    Prescrire Int; 2014 Apr; 23(148):97-100. PubMed ID: 24860895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
    Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of new drugs and indications in 2002: financial speculation or better patent care?
    Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?
    Paludetto MN; Olivier-Abbal P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2012 Dec; 21(12):1289-94. PubMed ID: 22961933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introduction to the theme "Precision medicine and prediction in pharmacology".
    Insel PA; Amara SG; Blaschke TF
    Annu Rev Pharmacol Toxicol; 2015; 55():11-4. PubMed ID: 25562643
    [No Abstract]   [Full Text] [Related]  

  • 38. Off-label prescriptions: patient safety first.
    Lancet Oncol; 2011 Sep; 12(9):825. PubMed ID: 21875558
    [No Abstract]   [Full Text] [Related]  

  • 39. A look back at 2009: one step forward, two steps back.
    Prescrire Int; 2010 Apr; 19(106):89-94. PubMed ID: 20568499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticholinergic risk: Use and limitations of anticholinergic scales.
    Villalba-Moreno AM; Alfaro-Lara ER; Santos-Ramos B
    Eur J Intern Med; 2015 Dec; 26(10):e65-6. PubMed ID: 26365371
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.